Medicinal significance of naturally occurring cyclotetrapeptides
Bioactive natural products are serendipitous drug candidates, which stimulate synthetic approaches for improving and supporting drug discovery and development. Therefore, the search for bioactive metabolites from different natural sources continues to play an important role in fashioning new medicinal agents. Several cyclic peptides were produced by organisms, such as β-defensins, gramicidin S, and tyrocidine A, and exhibited a wide range of bioactivities, such as antiviral activity against HIV-1, influenza A viruses, or antibacterial activity. Cyclic tetrapeptides are a class of natural products that were found to have a broad range of biological activities, promising pharmacokinetic properties, as well as interesting conformational dynamics and ability of slow inter-conversion to several different structures. Cyclooligopeptides, particularly medium ring-sized peptides, were obtained from marine microorganisms and exhibited a wide range of pharmacological properties, including antimicrobial and anti-dinoflagellate activities, cytotoxicity, and inhibitory activity against enzyme sortase B. Most of the naturally occurring cyclotetrapeptides are obtained from fungi. Some natural cyclic tetrapeptides were found to inhibit histone deacetylase (HDAC), which regulate the expression of genes. These compounds are very useful as cancer therapeutics. Various analogues of the natural cyclotetrapeptides were successfully synthesized to find novel lead compounds for pharmacological and biotechnological applications. Therefore, in this review, previously reported novel natural cyclotetrapeptides are briefly discussed, along with their important biological activities as drug candidates, together with their promising therapeutic properties. Moreover, their future perspective in drug discovery as potential therapeutic agents will be determined.
KeywordsCyclotetrapeptides Microorganisms Therapeutic properties Histone deacetylase inhibitors (HDACis) Bioactivities
The author is grateful to the German Academic Exchange Service (DAAD) for the PhD grant and Alexander von Humboldt Foundation, Germany, for the Georg Forster Postdoctoral Fellowship.
Compliance with ethical standards
Conflict of interest
The author declares that there are no potential conflicts of interests.
- 11.Tiffon CE, Adams JE, van der Fits L, Wen S, Townsend PA, Ganesan A, Hodges E, Vermeer MH, Packham G (2011) The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. Br J Pharmacol 162:1590–1602CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Itazaki H, Nagashima K, Sugita K, Yoshida H, Kawamura Y, Yasuda Y, Matsumoto K, Ishii K, Uotani N, Nakai H, Terui A (1990) Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. J Antibiot 43:1524–1532CrossRefPubMedGoogle Scholar
- 37.Fulton ND, Bollenbacher K, Templeton GE (1965) A metabolite from Alternaria tenuis that inhibits chlorophyll production. Phytopathology 55:49–51Google Scholar
- 38.Pinet E, Cavelier F, Verducci J, Girault G, Dubart L, Haraux F, Sigalat C, André F (1996) Synthesis, structure, and properties of MeSer1-tentoxin, a new cyclic tetrapeptide which interacts specifically with chloroplast F1 H+-ATPase differentiation of inhibitory and stimulating effects. Biochemistry 35:12804–12811CrossRefPubMedGoogle Scholar
- 45.Reddy CM, Murthy VNS, Mukkanti K, Acharyulu PVR (2007) Towards the total synthesis of halolitoralin-C. Indian J Chem 46B:1137–1142Google Scholar
- 46.Sun Y, Tian L, Huang YF, Sha Y, Pei YH (2006) A new cyclotetrapeptide from marine fungus Trichoderma reesei. Pharmazie 61:809–810Google Scholar
- 53.Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon BP, Mueller A, Schäberle TF, Hughes DE, Epstein S, Jones M, Lazarides L, Steadman VA, Cohen DR, Felix CR, Fetterman KA, Millett WP, Nitti AG, Zullo AM, Chen C, Lewis K (2015) A new antibiotic kills pathogens without detectable resistance. Nature 517:455–459CrossRefPubMedGoogle Scholar
- 55.Pérez-Victoria I, Martín J, González-Menéndez V, de Pedro N, El Aouad N, Ortiz-López FJ, Tormo JR, Platas G, Vicente F, Bills GF, Genilloud O, Goetz MA, Reyes F (2012) Isolation and structural elucidation of cyclic tetrapeptides from Onychocola sclerotica. J Nat Prod 75:1210–1214CrossRefPubMedGoogle Scholar
- 62.Lin Z, Reilly CA, Antemano R, Hughen RW, Marett L, Concepcion GP, Haygood MG, Olivera BM, Light A, Schmidt EW (2011) Nobilamides A–H, long-acting transient receptor potential vanilloid-1 (TRPV1) antagonists from mollusk-associated bacteria. J Med Chem 54:3746–3755CrossRefPubMedPubMedCentralGoogle Scholar
- 69.Yin WQ, Zou JM, She ZG, Vrijmoed LLP, Jones EBG, Lin YC (2005) Two cyclic peptides produced by the endophytic fungus #2221 from Castaniopsis fissa on the South China Sea Coast. Chin Chem Lett 16:219–222Google Scholar
- 73.Mitova M, Tommonaro G, De Rosa S (2003) A novel cyclopeptide from a bacterium associated with the marine sponge Ircinia muscarum. Z Naturforsch 58:740–745Google Scholar
- 74.Abdalla MA (2010) ent-Homoabyssomicins A and B, two new spirotetronates, khatmiamycin, a zoosporicidal naphthoquinone, and further new biologically active secondary metabolites from marine and terrestrial Streptomyces spp. Ph.D. thesis, Georg-August University of Goettingen. Cuvillier Verlag, Germany, 281 ppGoogle Scholar
- 82.Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 409:581–589CrossRefPubMedGoogle Scholar